to-BBB and Lundbeck to join forces on brain delivery of antibodies for CNS diseases

05-Jan-2010 - Netherlands

to-BBB and H. Lundbeck A/S are entering into a research collaboration to evaluate delivery of antibodies to the brain for central nervous system (CNS) diseases. This research could provide the backbone of new emerging therapies for unserved brain diseases.

“We are very pleased to collaborate with Lundbeck,” says Pieter Gaillard, CSO of to-BBB. “to-BBB’s brain delivery technology combined with Lundbeck’s strong knowledge in the area of CNS disorders, should result in further progress to improve the lives of patients with devastating brain diseases.”

Lundbeck is an international pharmaceutical company engaged in research to find new drugs for treatment of CNS disorders, including depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease. The collaboration with to-BBB could provide Lundbeck with an opportunity to improve the brain delivery of therapeutic antibodies addressing CNS diseases.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous